EGFR and non-small cell lung carcinoma: Recently, the identification of common driver mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase, leads to the development of many novel targeted therapies that has profoundly changed the survival outcomes of NSCLC patients, especially those with LUAD (4).